
( (S 
    (NP-SBJ (CD Two) (JJ Japanese) (NNS scientists) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (PRP they) )
          (VP (VBD discovered) 
            (NP 
              (NP (DT an) (NN antibody) )
              (SBAR 
                (WHNP-1 (IN that) )
                (, ,) 
                (S 
                  (PP-LOC (IN in) 
                    (NP (NN laboratory) (NN test-tube) (NNS experiments) ))
                  (, ,) 
                  (NP-SBJ-2 (-NONE- *T*-1) )
                  (VP (VBZ kills) 
                    (NP (JJ AIDS-infected) (NNS cells) )
                    (SBAR-TMP (IN while) 
                      (S 
                        (NP-SBJ (-NONE- *-2) )
                        (VP (VBG preserving) 
                          (NP (JJ healthy) (NNS cells) ))))))))))))
    (. .) ))
( (S 
    (SBAR-ADV (IN If) 
      (S 
        (NP-SBJ (JJ further) (NNS experiments) )
        (VP (VBP are) 
          (ADJP-PRD (JJ successful) ))))
    (, ,) 
    (NP-SBJ (DT the) (NN work) )
    (VP (MD would) 
      (VP (VB represent) 
        (NP 
          (NP (DT a) (JJ major) (NN advance) )
          (PP (IN in) 
            (NP 
              (NP (NN research) )
              (PP (IN on) 
                (NP (VBN acquired) (JJ immune) (NN deficiency) (NN syndrome) )))))))
    (. .) ))
( (S 
    (NP-SBJ-1 
      (NP (DT The) (NN drug) (NNP AZT) )
      (, ,) 
      (NP 
        (NP (DT the) (JJ only) (NN treatment) )
        (RRC 
          (ADVP-TMP (RB currently) )
          (PP (IN on) 
            (NP (DT the) (NN market) ))))
      (, ,) )
    (VP (VBZ claims) 
      (S 
        (NP-SBJ-3 (-NONE- *-1) )
        (VP 
          (ADVP (RB only) )
          (VP (TO to) 
            (VP (VB help) 
              (S 
                (NP-SBJ (-NONE- *-3) )
                (VP (VB stop) 
                  (NP 
                    (NP (DT the) (NN spread) )
                    (PP (IN of) 
                      (NP (NNP AIDS) )))))))
          (, ,) (RB not) 
          (VP (TO to) 
            (VP (VB cure) 
              (NP (PRP it) ))))))
    (. .) ))
( (S (CC But) 
    (NP-SBJ 
      (NP 
        (NP (JJ several) (NNS analysts) )
        (CC and) 
        (NP (JJ Japanese) (NNS scientists) ))
      (ADJP (JJ familiar) 
        (PP (IN with) 
          (NP 
            (NP (DT the) (NN study) )
            (, ,) 
            (SBAR 
              (WHNP-2 (WDT which) )
              (S 
                (NP-SBJ-1 (-NONE- *T*-2) )
                (VP (VBD was) 
                  (VP (VBN announced) 
                    (NP (-NONE- *-1) )
                    (PP-LOC (IN at) 
                      (NP 
                        (NP (DT a) (NN conference) )
                        (PP-LOC (IN in) 
                          (NP (NNP Nagoya) ))))
                    (NP-TMP (NN yesterday) )))))
            (, ,) ))))
    (VP (VBD expressed) 
      (NP (NN skepticism) )
      (PP-CLR (IN over) 
        (NP 
          (NP (DT the) (NN significance) )
          (PP (IN of) 
            (NP (DT the) (NNS results) )))))
    (. .) ))
( (S (CC And) 
    (NP-SBJ 
      (NP (DT the) (NNS researchers) )
      (NP (PRP themselves) ))
    (VP (VBD acknowledged) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (PRP they) )
          (ADVP (RB still) )
          (VP (MD must) 
            (VP (VB do) 
              (NP 
                (ADJP (RB much) (JJR more) )
                (NN work) )
              (SBAR-TMP (IN before) 
                (S 
                  (NP-SBJ (PRP they) )
                  (VP (MD can) 
                    (VP (VB say) 
                      (SBAR (IN whether) 
                        (S 
                          (NP-SBJ (DT the) (NN treatment) )
                          (VP (MD would) 
                            (ADVP (RB actually) )
                            (VP (VB cure) 
                              (NP (NNS humans) ))))))))))))))
    (. .) ))
( (S 
    (NP-SBJ 
      (NP (NNP Shin) (NNP Yonehara) )
      (, ,) 
      (NP 
        (NP (DT a) (NN research) (NN scientist) )
        (PP-LOC (IN at) 
          (NP 
            (NP (DT the) (NNP Tokyo) (NNP Metropolitan) (NNP Institute) )
            (PP (IN of) 
              (NP (NNP Medical) (NNP Science) )))))
      (, ,) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ 
            (NP (DT the) (NN antibody) )
            (SBAR 
              (WHNP-2 (-NONE- 0) )
              (S 
                (NP-SBJ (PRP he) )
                (VP (VBD discovered) 
                  (NP (-NONE- *T*-2) )))))
          (VP (VBZ works) 
            (PP-MNR (IN by) 
              (S-NOM 
                (NP-SBJ (-NONE- *) )
                (VP (VBG recognizing) 
                  (NP 
                    (NP (DT an) (NN antigen) )
                    (VP (VBN called) 
                      (S 
                        (NP-SBJ (-NONE- *) )
                        (NP-PRD (DT a) (NN Fas-antigen) )))
                    (, ,) 
                    (SBAR 
                      (WHNP-1 (WDT which) )
                      (S 
                        (NP-SBJ (-NONE- *T*-1) )
                        (VP (VBZ is) 
                          (ADJP-PRD (JJ characteristic) 
                            (PP (IN of) 
                              (NP (DT an) (JJ infected) (NN cell) ))))))))))))))
    (. .) ))
( (S 
    (NP-SBJ (DT The) (NN antibody) )
    (ADVP-TMP (RB then) )
    (VP (VBZ kills) 
      (NP (DT the) (NN cell) ))
    (. .) ))
( (S 
    (NP-SBJ 
      (NP (NNP Dr.) (NNP Yonehara) )
      (CC and) 
      (NP 
        (NP (PRP$ his) (NN partner) )
        (, ,) 
        (NP 
          (NP (NNP Nobuyuki) (NNP Kobayashi) )
          (PP (IN of) 
            (NP (NNP Yamaguchi) (NNP University) )))
        (, ,) ))
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (PRP$ their) (NNS experiments) )
          (VP (VBD showed) 
            (SBAR (IN that) 
              (S 
                (NP-SBJ (DT the) (NN antibody) )
                (VP (VBD wiped) 
                  (PRT (RP out) )
                  (NP 
                    (NP (DT an) (NN average) )
                    (PP (IN of) 
                      (NP 
                        (NP (CD 60) (NN %) )
                        (PP (IN of) 
                          (NP (JJ AIDS-infected) (NNS cells) )))))
                  (PP-TMP (IN within) 
                    (NP (CD three) (NNS days) )))))))))
    (. .) ))
( (S 
    (S-TPC-1 
      (PP-LOC (IN In) 
        (NP 
          (NP (DT some) )
          (PP (IN of) 
            (NP (DT the) (NNS experiments) ))))
      (, ,) 
      (NP-SBJ (PRP it) )
      (VP (VBD killed) 
        (NP 
          (QP (RB almost) (PDT all) )
          (DT the) (JJ infected) (NNS cells) )))
    (, ,) 
    (NP-SBJ (DT the) (NNS researchers) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S (-NONE- *T*-1) )))
    (. .) ))
( (S 
    (ADVP (RB Meanwhile) )
    (, ,) 
    (NP-SBJ-1 
      (NP 
        (QP (JJR fewer) (IN than) (CD 10) )
        (NN %) )
      (PP (IN of) 
        (NP (DT the) (JJ healthy) (NNS cells) )))
    (VP (VBD were) 
      (VP (VBN killed) 
        (NP (-NONE- *-1) )))
    (. .) ))
( (S 
    (NP-SBJ (DT The) (CD two) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (PRP they) )
          (VP (MD must) 
            (VP 
              (VP 
                (ADVP (RB still) )
                (VB do) 
                (NP (JJR more) (NN laboratory) (NNS tests) ))
              (, ,) (RB then) 
              (VP (NN experiment) 
                (PP-CLR (IN on) 
                  (NP (NNS animals) ))))))))
    (. .) ))
( (S 
    (NP-SBJ (PRP They) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ-1 (PRP they) )
          (VP (VBD hoped) 
            (S 
              (NP-SBJ (-NONE- *-1) )
              (VP (TO to) 
                (VP (VB conduct) 
                  (NP (NNS tests) )
                  (PP-CLR (IN on) 
                    (NP 
                      (NP (JJ human) (NNS patients) )
                      (PP-LOC (IN in) 
                        (NP (DT the) (NNP U.S.) ))))
                  (PP-TMP (IN by) 
                    (NP (JJ late) (JJ next) (NN year) )))))))))
    (. .) ))
( (S 
    (S-TPC-2 
      (NP-SBJ-1 (NNP Japan) )
      (VP (VBZ does) (RB n't) 
        (VP (VB have) 
          (NP (JJ enough) (NNP AIDS) (NNS patients) 
            (S 
              (NP-SBJ (-NONE- *-1) )
              (VP (TO to) 
                (VP (VB do) 
                  (NP (JJ significant) (NN experimentation) )
                  (PP-LOC (IN in) 
                    (NP (DT that) (NN country) )))))))))
    (, ,) 
    (NP-SBJ (PRP they) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S (-NONE- *T*-2) )))
    (. .) ))
( (S 
    (NP-SBJ (DT The) (NN announcement) )
    (VP 
      (VP (VBD got) 
        (NP (JJ wide) (NN exposure) )
        (PP-LOC (IN in) 
          (NP (DT the) (JJ Japanese) (NNS media) )))
      (, ,) 
      (CC and)
      (VP 
        (ADVP (RB even) )
        (VBD moved) 
        (NP (DT some) (JJ pharmaceutical) (NNS stocks) )
        (NP-TMP (NN yesterday) )))
    (. .) ))
( (S (CC But) 
    (NP-SBJ 
      (NP (NNP Takashi) (NNP Kitamura) )
      (, ,) 
      (NP 
        (NP 
          (NP (NN director) )
          (PP (IN of) 
            (NP 
              (NP (DT the) (NN biology) (NN department) )
              (PP-LOC (IN at) 
                (NP 
                  (NP 
                    (NP (NNP Japan) (POS 's) )
                    (NNP National) (NNP Institute) )
                  (PP (IN of) 
                    (NP (NNP Health) )))))))
        (CC and) 
        (NP 
          (NP (NN secretary) )
          (PP (IN of) 
            (NP 
              (NP (DT the) (NN government) (POS 's) )
              (JJ AIDS-research) (NN center) ))))
      (, ,) )
    (VP (VBD said) 
      (, ,)
      (`` ``) 
      (S 
        (NP-SBJ (PRP I) )
        (VP (VBP 'm) (RB not) 
          (ADJP-PRD (RB so) (JJ optimistic) 
            (PP (IN of) 
              (NP 
                (NP (PRP$ its) (JJ future) (NN use) )
                (PP-LOC (IN in) 
                  (NP (JJ therapeutic) (NNS methods) ))))))))
    (. .) ('' '') ))
( (S 
    (NP-SBJ (PRP He) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ-1 (DT some) (JJ infected) (NNS cells) )
          (VP 
            (VP (MD may) (RB not) 
              (VP (VB have) 
                (NP (DT the) (JJ relevant) (NN antigen) )))
            (CC and) 
            (VP 
              (ADVP (RB so) )
              (MD would) (RB n't) 
              (VP (VB be) 
                (VP (VBN killed) 
                  (NP (-NONE- *-1) )
                  (PP-TMP 
                    (ADVP (RB even) )
                    (IN after) 
                    (NP 
                      (NP (NN exposure) )
                      (PP (TO to) 
                        (NP (DT the) (NN antibody) )))))))))))
    (. .) ))
( (SINV (`` ``) 
    (S-TPC-2 
      (NP-SBJ-1 (DT The) (NNS results) )
      (VP (VBP seem) 
        (S 
          (NP-SBJ (-NONE- *-1) )
          (VP (TO to) 
            (VP (VB be) 
              (ADJP-PRD (RB very) (JJ premature) ))))))
    (, ,) ('' '') 
    (VP (VBD said) 
      (S (-NONE- *T*-2) ))
    (NP-SBJ 
      (NP (NNP Mitsuru) (NNP Miyata) )
      (, ,) 
      (NP 
        (NP (NN editor) )
        (PP (IN of) 
          (NP 
            (NP (NNP Nikkei) (NNP Biotechnology) )
            (, ,) 
            (NP (DT a) (VBG leading) (JJ Japanese) (NN industry) (NN newsletter) )))))
    (. .) ))
( (S 
    (NP-SBJ (NNP Dr.) (NNP Kobayashi) )
    (VP (VBD responded) 
      (SBAR (IN that) 
        (S 
          (NP-SBJ (PRP he) )
          (VP (VBD thought) 
            (SBAR (-NONE- 0) 
              (S 
                (NP-SBJ (DT the) (NN antibody) )
                (VP (MD could) 
                  (ADVP (RB potentially) )
                  (VP (VB kill) 
                    (NP (DT all) (JJ infected) (NNS cells) )))))))))
    (. .) ))
( (S (CC But) 
    (NP-SBJ 
      (NP (PRP he) )
      (CC and) 
      (NP (NNP Dr.) (NNP Yonehara) ))
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (NP-SBJ (EX there) )
          (VP (VBD were) 
            (ADVP (RB still) )
            (NP-PRD 
              (NP (JJ several) (NNS uncertainties) )
              (, ,) 
              (RRC 
                (ADVP (RB particularly) )
                (PP (VBG regarding) 
                  (NP (JJ possible) (NN side) (NNS effects) ))))))))
    (. .) ))
( (SINV (`` ``) 
    (S-TPC-1 
      (S 
        (NP-SBJ (PRP$ Our) (NN antibody) )
        (VP 
          (ADVP (RB specifically) )
          (VBD killed) 
          (NP (JJ infected) (NNS cells) )
          (PP-MNR (IN at) 
            (NP (DT a) 
              (ADJP (RB very) (JJ low) )
              (NN dose) ))))
      (, ,) (CC but) 
      (S 
        (NP-SBJ (PRP it) )
        (VP (MD can) 
          (ADVP (RB also) )
          (VP (VB kill) 
            (NP (JJ other) (NNS cells) )))))
    (, ,) ('' '') 
    (VP (VBD said) 
      (S (-NONE- *T*-1) ))
    (NP-SBJ (NNP Dr.) (NNP Yonehara) )
    (. .) ))
( (S (`` ``) 
    (NP-SBJ (PRP We) )
    (VP (VBP do) (RB n't) 
      (VP (VB know) 
        (NP 
          (NP (DT the) (NN effect) )
          (PP (IN of) 
            (NP (PRP$ our) (NN antibody) ))
          (PP (IN on) 
            (NP (DT the) (JJ human) (NN body) )))))
    (. .) ('' '') ))
( (S 
    (S 
      (NP-SBJ-1 (NNP AIDS) )
      (VP (VBZ is) (RB n't) 
        (VP (VBN considered) 
          (S 
            (NP-SBJ (-NONE- *-1) )
            (NP-PRD 
              (NP (DT a) (JJ widespread) (NN problem) )
              (PP-LOC (IN in) 
                (NP (NNP Japan) )))))))
    (: --) 
    (S 
      (NP-SBJ (DT the) (NN government) )
      (VP (VBZ reports) 
        (NP 
          (NP 
            (QP (IN about) (CD 1,000) )
            (VBN known) (NNS carriers) )
          (PP (IN of) 
            (NP (DT the) (NN virus) )))))
    (: --) (CC but) 
    (S 
      (NP-SBJ-2 (JJ many) (NNS companies) )
      (VP (VBP have) 
        (VP (VBN poured) 
          (NP (JJ substantial) (NNS resources) )
          (PP-CLR (IN into) 
            (NP (NN research) ))
          (PP-TMP (IN in) 
            (NP (JJ recent) (NNS years) ))
          (, ,) 
          (S-ADV 
            (NP-SBJ-3 (-NONE- *-2) )
            (VP (VBG hoping) 
              (S 
                (NP-SBJ (-NONE- *-3) )
                (VP (TO to) 
                  (VP (VB cash) 
                    (PRT (RP in) )
                    (PP-CLR (IN on) 
                      (NP (DT a) (JJ possible) (NN cure) ))))))))))
    (. .) ))
( (S 
    (NP-SBJ (NNP Dr.) (NNP Kitamura) )
    (VP (VBD said) 
      (SBAR 
        (SBAR (-NONE- 0) 
          (S 
            (NP-SBJ 
              (QP (IN about) (CD 35) )
              (NNS projects) )
            (VP (VBP are) 
              (ADVP-TMP (RB currently) )
              (PP-PRD (IN under) 
                (NP (NN way) ))
              (PP-LOC (IN in) 
                (NP (NNP Japan) )))))
        (, ,) 
        (CC and)
        (SBAR (IN that) 
          (S 
            (NP-SBJ 
              (NP (JJ Japanese) (NNS researchers) )
              (PP-TMP (IN in) 
                (NP (DT the) (JJ past) (NN year) )))
            (VP (VBP have) 
              (VP (VBN made) 
                (S 
                  (ADJP-PRD (JJ available) 
                    (PP (-NONE- *ICH*-1) )
                    (PP (-NONE- *ICH*-2) ))
                  (NP-SBJ (CD three) (JJ possible) (NNS cures) )
                  (PP-1 (TO to) 
                    (NP (JJ American) (NNS researchers) ))
                  (PP-2 (IN for) 
                    (NP (JJ clinical) (NNS tests) )))))))))
    (. .) ))
( (S 
    (NP-SBJ (PRP He) )
    (VP (VBD said) 
      (SBAR (IN that) 
        (S 
          (SBAR-TMP 
            (WHADVP-1 (WRB when) )
            (S 
              (NP-SBJ 
                (NP (NNS scientists) )
                (PP (IN from) 
                  (NP (DT the) (CD two) (NNS countries) )))
              (VP (VBP meet) 
                (ADVP (RB again) )
                (PP-TMP (IN in) 
                  (NP (NNP January) ))
                (PP-LOC (IN in) 
                  (NP (NNP New) (NNP Orleans) ))
                (ADVP-TMP (-NONE- *T*-1) ))))
          (, ,) 
          (NP-SBJ (DT the) (NNP Japanese) )
          (VP (MD will) 
            (VP (VB present) 
              (NP 
                (ADJP 
                  (QP (IN at) (JJS least) (CD three) )
                  (JJR more) )
                (NNS drugs) )
              (PP-CLR (IN for) 
                (NP (JJ human) (NN testing) )))))))
    (. .) ))
( (S 
    (NP-SBJ (NNP AZT) )
    (VP (VBZ is) 
      (NP-PRD 
        (NP 
          (NP (DT the) (NN world) (POS 's) )
          (JJ only) (NN prescription) (NN medicine) )
        (VP (VBN approved) 
          (NP (-NONE- *) )
          (PP-CLR (IN for) 
            (S-NOM 
              (NP-SBJ (-NONE- *) )
              (VP (VBG treating) 
                (NP (DT the) (NN disease) )))))))
    (. .) ))
( (S 
    (NP-SBJ 
      (NP (NNP Wellcome) (NNP PLC) )
      (, ,) 
      (NP (DT a) (JJ major) (JJ British) (NN pharmaceutical) (NN maker) )
      (, ,) )
    (VP (VBZ sells) 
      (NP (DT the) (NN drug) )
      (PP-MNR (IN under) 
        (NP 
          (NP (DT the) (NN name) )
          (NP (NNP Retrovir) ))))
    (. .) ))
( (S 
    (NP-SBJ-1 (DT A) (NNP Wellcome) (NN spokesman) )
    (VP (VBD declined) 
      (S 
        (NP-SBJ (-NONE- *-1) )
        (VP (TO to) 
          (VP (VB comment) 
            (PP-CLR (IN on) 
              (NP 
                (NP (DT the) (NN discovery) )
                (PP (IN of) 
                  (NP (DT the) (NN antibody) ))
                (PP-LOC (IN in) 
                  (NP (NNP Japan) ))))))))
    (. .) ))
( (S (CC But) 
    (NP-SBJ 
      (NP (NNP Andrew) (NNP Porter) )
      (, ,) 
      (NP 
        (NP (DT a) (NN drug-industry) (NN analyst) )
        (PP-LOC (IN at) 
          (NP 
            (NP (NNP Nikko) (NNPS Securities) (NNP Co.) )
            (PP-LOC (IN in) 
              (NP (NNP London) )))))
      (, ,) )
    (VP (VBD said) 
      (SBAR (-NONE- 0) 
        (S 
          (SBAR-ADV (IN if) 
            (S 
              (NP-SBJ-2 (DT the) (NN product) )
              (VP (VBD were) 
                (S 
                  (NP-SBJ-1 (-NONE- *-2) )
                  (VP (TO to) 
                    (VP (VB be) 
                      (VP 
                        (ADVP-MNR (RB successfully) )
                        (VBN developed) 
                        (NP (-NONE- *-1) ))))))))
          (NP-SBJ (PRP it) )
          (VP (MD would) 
            (VP (VB represent) (`` ``) 
              (NP 
                (NP (DT a) (JJ potential) (NN threat) )
                (PP (TO to) 
                  (NP 
                    (NP (DT the) (JJ long-term) (NN viability) )
                    (PP (IN of) 
                      (NP (NNP Retrovir) ))))))))))
    (. .) ))
